



Fabrazyme in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

RARE DISEASE · FABRY DISEASE

The clinical situation

Fabrazyme (agalsidase beta) is an FDA-approved recombinant alpha-galactosidase A enzyme replacement therapy for Fabry disease, dosed 1 mg/kg IV every two weeks. Manufactured by Sanofi. Weight-based dosing, cold-chain shipment, and renal / cardiac monitoring are required. Infusion-related reactions are managed with premedication and rate titration.

The pathway, 5 steps

- 1 Consultation & diagnostic confirmation.** Treating metabolic / genetics specialist confirms GLA variant and Fabry phenotype; weight-based dose calculated, renal and cardiac baselines documented.
- 2 Infusion centre confirmed.** A Saudi tertiary centre (Riyadh, Jeddah, or Eastern Province) commits to biweekly infusion slots and monitoring.
- 3 SFDA named-patient application.** Clinical rationale, genetic report, dose calculation, and product details are filed for SFDA review.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to infusion schedule.
- 5 Infusion & monitoring.** Biweekly IV infusions under specialist supervision; renal function and cardiac imaging monitored per label.

Indicative economics

Reference US cash-pay range: USD 17,000–22,000 per infusion (weight-based) drug-only. Cold-chain logistics, SFDA documentation, infusion-centre fees, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-infusion timing

7–14 days from a complete SFDA application to first-infusion delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** SFDA named-patient package with genetic confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Fabrazyme × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/fabrazyme-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team